Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 1
1976 2
1977 4
1978 2
1979 2
1980 4
1982 5
1983 2
1984 9
1985 2
1986 4
1987 5
1988 5
1989 5
1990 7
1991 10
1992 18
1993 12
1994 20
1995 15
1996 17
1997 28
1998 38
1999 36
2000 40
2001 42
2002 55
2003 55
2004 62
2005 74
2006 83
2007 99
2008 89
2009 72
2010 78
2011 95
2012 100
2013 102
2014 104
2015 126
2016 120
2017 125
2018 150
2019 171
2020 186
2021 239
2022 197
2023 186
2024 73

Text availability

Article attribute

Article type

Publication date

Search Results

2,588 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Dermatitis, atopic, 7"
Page 1
Overview of atopic dermatitis.
Avena-Woods C. Avena-Woods C. Am J Manag Care. 2017 Jun;23(8 Suppl):S115-S123. Am J Manag Care. 2017. PMID: 28978208 Free article. Review.
Atopic dermatitis (AD), also known as atopic eczema, is a chronic relapsing inflammatory skin condition. ...AD has a wide-ranging impact on a patient's quality of life and the burden from direct and indirect costs (approximately $37.7 billion in out-of …
Atopic dermatitis (AD), also known as atopic eczema, is a chronic relapsing inflammatory skin condition. ...AD has a wi …
Children atopic dermatitis: Diagnosis, mimics, overlaps, and therapeutic implication.
Napolitano M, Fabbrocini G, Martora F, Genco L, Noto M, Patruno C. Napolitano M, et al. Dermatol Ther. 2022 Dec;35(12):e15901. doi: 10.1111/dth.15901. Epub 2022 Oct 13. Dermatol Ther. 2022. PMID: 36200594 Free PMC article. Review.
Atopic dermatitis (AD) is a chronic inflammatory, itching skin with a significant psychosocial impact on patients and relatives. In adults and adolescents besides flexural eczema, head and neck eczema, and hand eczema, which are the most frequent clinical phenotypes …
Atopic dermatitis (AD) is a chronic inflammatory, itching skin with a significant psychosocial impact on patients and relative …
Phenotypes of Atopic Dermatitis Depending on the Timing of Onset and Progression in Childhood.
Roduit C, Frei R, Depner M, Karvonen AM, Renz H, Braun-Fahrländer C, Schmausser-Hechfellner E, Pekkanen J, Riedler J, Dalphin JC, von Mutius E, Lauener RP; the PASTURE study group; Hyvärinen A, Kirjavainen P, Remes S, Roponen M, Dalphin ML, Kaulek V, Ege M, Genuneit J, Illi S, Kabesch M, Schaub B, Pfefferle PI, Doekes G. Roduit C, et al. JAMA Pediatr. 2017 Jul 1;171(7):655-662. doi: 10.1001/jamapediatrics.2017.0556. JAMA Pediatr. 2017. PMID: 28531273 Free PMC article.
IMPORTANCE: Atopic dermatitis is an inflammatory, pruritic skin disease that often occurs in early infancy with a chronic course. ...MAIN OUTCOMES AND MEASURES: The latent class analysis was used to identify subtypes of atopic dermatitis in childhood b …
IMPORTANCE: Atopic dermatitis is an inflammatory, pruritic skin disease that often occurs in early infancy with a chronic cour …
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, Moate R, van der Merwe R. Wollenberg A, et al. J Allergy Clin Immunol. 2019 Jan;143(1):135-141. doi: 10.1016/j.jaci.2018.05.029. Epub 2018 Jun 12. J Allergy Clin Immunol. 2019. PMID: 29906525 Free article. Clinical Trial.
BACKGROUND: IL-13 has an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human mAb that potently and specifically neutralizes IL-13. ...Participants treated with 300 mg of tralokinumab demonstrated improvements in SCORAD, Dermatology L …
BACKGROUND: IL-13 has an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human mAb that potentl …
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A. Blauvelt A, et al. Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14. Am J Clin Dermatol. 2022. PMID: 35567671 Free PMC article. Clinical Trial.
Atopic dermatitis remains a problem for many adolescent patients, even if they use a number of different treatments. ...Almost half of the patients achieved skin that was clear or almost clear of atopic dermatitis during the study. But their atopic …
Atopic dermatitis remains a problem for many adolescent patients, even if they use a number of different treatments. ...Almost …
Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial.
Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, Schauer U, Qaqundah P, Poulin Y, Kristjansson S, von Berg A, Nieto A, Boguniewicz M, Paller AS, Dakovic R, Ring J, Luger T. Sigurgeirsson B, et al. Pediatrics. 2015 Apr;135(4):597-606. doi: 10.1542/peds.2014-1990. Epub 2015 Mar 23. Pediatrics. 2015. PMID: 25802354 Free article. Clinical Trial.
BACKGROUND AND OBJECTIVES: Atopic dermatitis (AD) primarily affects infants and young children. ...The PIM group required substantially fewer steroid days than the TCS group (7 vs 178). The profile and frequency of adverse events was similar in the 2 groups; …
BACKGROUND AND OBJECTIVES: Atopic dermatitis (AD) primarily affects infants and young children. ...The PIM group required subs …
Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Oykhman P, Dookie J, Al-Rammahy H, de Benedetto A, Asiniwasis RN, LeBovidge J, Wang J, Ong PY, Lio P, Gutierrez A, Capozza K, Martin SA, Frazier W, Wheeler K, Boguniewicz M, Spergel JM, Greenhawt M, Silverberg JI, Schneider L, Chu DK. Oykhman P, et al. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2657-2666.e8. doi: 10.1016/j.jaip.2022.06.044. Epub 2022 Jul 19. J Allergy Clin Immunol Pract. 2022. PMID: 35987995
BACKGROUND: The influence of diet on atopic dermatitis (AD) is complex, and the use of dietary elimination as a treatment has conflicting views. ...RESULTS: Ten RCT (n = 599; baseline median of study mean age, 1.5 years; median of study mean SCOring Atopic …
BACKGROUND: The influence of diet on atopic dermatitis (AD) is complex, and the use of dietary elimination as a treatment has …
Causal Associations between Vitamin D Levels and Psoriasis, Atopic Dermatitis, and Vitiligo: A Bidirectional Two-Sample Mendelian Randomization Analysis.
Ren Y, Liu J, Li W, Zheng H, Dai H, Qiu G, Yu D, Yao D, Yin X. Ren Y, et al. Nutrients. 2022 Dec 11;14(24):5284. doi: 10.3390/nu14245284. Nutrients. 2022. PMID: 36558443 Free PMC article.
BACKGROUND: Vitamin D level has been reported to be associated with psoriasis, atopic dermatitis, and vitiligo. However, its causal relationship with the risk of these three diseases remains unclear. ...CONCLUSIONS: This study reported causal relationships between c …
BACKGROUND: Vitamin D level has been reported to be associated with psoriasis, atopic dermatitis, and vitiligo. However, its c …
Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population.
Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, Grayson MH, Margolis DJ, Mitchell L, Silverberg JI, Schwartz L, Simpson EL, Ong PY. Chiesa Fuxench ZC, et al. J Invest Dermatol. 2019 Mar;139(3):583-590. doi: 10.1016/j.jid.2018.08.028. Epub 2018 Oct 30. J Invest Dermatol. 2019. PMID: 30389491 Free article.
Among 1,278 participating adults, the prevalence (95% confidence interval) of atopic dermatitis was 7.3% (5.9-8.8). Overall, 60.1% (56.1-64.1) of participants were classified as having mild, 28.9% (25.3-32.7) as having moderate, and 11% as having sever …
Among 1,278 participating adults, the prevalence (95% confidence interval) of atopic dermatitis was 7.3% (5.9-8.8). Ove …
The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.
Alves C, Penedones A, Mendes D, Batel Marques F. Alves C, et al. Eur J Clin Pharmacol. 2022 Dec;78(12):1923-1933. doi: 10.1007/s00228-022-03400-4. Epub 2022 Oct 7. Eur J Clin Pharmacol. 2022. PMID: 36207461
PURPOSE: Janus kinase (JAK) inhibitors have been developed to treat moderate to severe atopic dermatitis, but there is little evidence comparing the safety profile of these drugs. The aim of this study is to compare the relative safety of the different systemic JAK …
PURPOSE: Janus kinase (JAK) inhibitors have been developed to treat moderate to severe atopic dermatitis, but there is little …
2,588 results